Cystic Fibrosis clinical trials at UCSF
5 in progress, 2 open to eligible people
4D-710 in Adult Patients With Cystic Fibrosis
open to eligible people ages 18 years and up
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.
San Francisco, California and other locations
Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
open to eligible people ages 12 years and up
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research involvement for people with CF who do not take CFTR modulators, engage them in research, and give them an opportunity to learn about what is involved in participating in a CF research study.
San Francisco, California and other locations
Long-term Safety and Efficacy of VX-121 Combination Therapy
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.
San Francisco, California and other locations
Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection
Sorry, not accepting new patients
The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.
San Francisco, California and other locations
Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
Sorry, accepting new patients by invitation only
The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor lung that were preserved and transported within the LUNGguard system, as well as retrospective standard of care patients
San Francisco, California and other locations
Our lead scientists for Cystic Fibrosis research studies include Jonathan Singer, MD.
Last updated: